ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ALXO / financials
MGNX (24) CUE (29) PDSB (46) CNTN (33) ⌘ Pro Terminal β†’

ALX Oncology Holdings Inc. (ALXO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.37 +12.30% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.40

ALX Oncology Holdings Inc. (ALXO) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $152.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALXO Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ALXO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, ALX Oncology Holdings Inc. (NASDAQ: ALXO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.37 (+12.30% 1D, market cap $152.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, ALXO ranks #395 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ALXO compare to MGNX and CUE in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALXO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, MGNX (MacroGenics Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $152.9M) and CUE (Cue Biopharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M). Among the 5-stock peer group, ALXO leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALXO?
β–Ό

Per ALXO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001810182), ALX Oncology Holdings Inc. generated $291.3M in revenue (-27.0% YoY), -$101.7M in net income, and -$84.4M in free cash flow against $59.0M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.40 (+2.02%)🧬 Disciplined Float (+0.16% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (44/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510044
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk C-
Cash (8)Whales (5)SEC (13)Macro (11)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-6.6% Base Target
$3 Bull$1 Base$1 Bear
πŸ“¬ FREE ALXO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ALXO)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
πŸ” WHY ALXO SCORES 44/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–² #2 Bullish Driver: Macro Regime Fit+11/20 pts (25% of score)

FRED Regime Γ— Technicals: 28% of 52W Range β€’ RSI-14 at 47.4 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
36
Grade E$1.26-9.5% Next Q
Q2 (-2Q)
39
Grade E$1.14-0.9% Next Q
Q3 (-1Q)
41
Grade D$1.13+21.2% Next Q
Current
44
Grade D$1.37-6.5% Hist 90D Ξ±
Trajectory: E (36) β†’ D (44)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ALXO Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ALXO currently carries a cautious 44/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.50) and Max Pain ($1.44) forces dealer call-delta covering toward $2.79.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALXOβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œALXO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How ALXO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$291.3MGross Profit $151.5M (52%)Cost of Sales $139.8MOp Profit $0 (0%)OpEx (R&D/SG&A) $151.5MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $476.8M
FY24
Rev $398.9M
FY25
Rev $291.3M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$291.3M52%-35.7%-$101.7M-$84.4M-45%
FY 2024$398.9M52%-35.7%-$134.8M-$122.4M-45%
FY 2023$476.8M52%-35.7%-$160.8M-$130.4M-35%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALXO)

  • βœ“Walkthrough of ALXO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ALXO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.13%β–Ό DESCENDING CHANNEL
2026-11-03O $1.22H $1.37L $1.22C $1.37VOL 422.2K
RES: $1.75SUP: $0.79SMA50: $1.50SMA200: $1.82
$2.52$2.07$1.62$1.17$0.72RES $1.75SUP $0.79$1.372026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALXO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ALXO Butterfly Map β†’ + Track ALXO β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -27.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ALXO today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ALXO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALXO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALXO)

Health Care Rank #395 of 1015 βš”οΈ MGNX vs ALXO Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ALXO vs. MGNX, CUE, PDSB, CNTN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, ALX Oncology Holdings Inc. (ALXO) ranks #395 by composite RQD confidence (44/100, grade D) and #602 by equity capitalization ($152.4M). Within this direct 5-issuer industry benchmark cohort, ALXO leads on earnings valuation at N/A trailing P/E, while CNTN leads on capital efficiency and profitability with -4.1% ROIC and β€” gross margin. PDSB currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with ALXO at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ALXO ACTIVE
ALX Oncology Holdings Inc.
D 44/100 β€” β€” -35.0% +12.30% $152.4M Benchmark Subject
MGNX
MacroGenics Inc.
E 24/100 β€” 96.0% -35.0% -2.92% $152.9M /mgnx-vs-alxo β†’
CUE
Cue Biopharma Inc.
E 29/100 β€” β€” -35.0% -6.95% $151.6M /cue-vs-alxo β†’
PDSB
PDS Biotechnology Corporation
D 46/100 β€” β€” -35.0% -4.86% $151.2M /pdsb-vs-alxo β†’
CNTN
Canton Strategic Holdings Inc.
E 33/100 β€” β€” -4.1% +4.62% $155.4M /cntn-vs-alxo β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001810182 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ALX Oncology Holdings Inc. (ALXO) reported GAAP revenue of $291.3M (-27.0% vs. FY2024 revenue of $398.9M , and -38.9% cumulative change since FY2023) , GAAP net income of -$101.7M, operating cash flow of -$84.1M, and free cash flow of -$84.4M (+31.1% YoY). On the balance sheet, ALXO closed FY2025 with $59.0M in total assets against $4.5M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $291.3M -$101.7M -$84.1M -$84.4M $59.0M $4.5M
FY2024 (FY) 2024-12-31 $398.9M -$134.8M -$121.9M -$122.4M $147.8M $9.5M
FY2023 (FY) 2023-12-31 $476.8M -$160.8M -$130.4M -$130.4M β€” β€”

3. ALXO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALXO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ALX Oncology Holdings Inc. (NASDAQ: ALXO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.37 (+12.30% 1D, market cap $152.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, ALXO ranks #395 in composite RQD confidence.

How does ALXO compare to MGNX and CUE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALXO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, MGNX (MacroGenics Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $152.9M) and CUE (Cue Biopharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M). Among the 5-stock peer group, ALXO leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALXO?

Per ALXO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001810182), ALX Oncology Holdings Inc. generated $291.3M in revenue (-27.0% YoY), -$101.7M in net income, and -$84.4M in free cash flow against $59.0M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALXO trading relative to its 50-day, 200-day, and 52-week technical levels?

ALXO last traded at $1.37 (+12.30% on volume of 1,610,253 shares), positioning the stock -8.67% below its 50-day simple moving average ($1.50) and -24.73% below its 200-day simple moving average ($1.82). Across its 52-week range of $0.86 to $2.66, ALXO sits at the 28.3% percentile with a 14-day RSI of 47.4 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.20 to $1.54).

Direct Sub-Reports: ALXO RQD Cockpit ALXO 12M Forecast ALXO Earnings & Move ALXO Dividends & DRIP ALXO Insiders & 13F ALXO Whale Options ALXO Profit Sankey ALXO News & Why
ROARABLE RATING BRIEF β€’ RQD 44/100 (D) βœ“ SEC XBRL & RQD VERIFIED

ALXO β€” ALX Oncology Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ALX Oncology Holdings Inc. (ALXO) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.37 (+12.30% 1D, market capitalization $152.4M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of 0.17x.

2. Business Model, Unit Margins & SEC Financial Trajectory

ALX Oncology Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Products, customers, and revenue model are not described in the source data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ALX Oncology Holdings Inc. (ALXO) reported $291.3M in annual revenue (up from $398.9M in FY2024, -27.0% YoY) and -$101.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($476.8M revenue, -$160.8M net income) through FY2025, ALXO scaled operating cash flow to -$84.1M and free cash flow to -$84.4M, backed by $59.0M in total assets against $4.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 44/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.86 – $2.66 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ALXO carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can ALXO sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $291.3M and free cash flow of -$84.4M, how will capital allocation balance growth reinvestment against $4.5M in total debt?
  • Key Question #3: How sensitive is ALXO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ALXO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ALX Oncology Holdings Inc. (ALXO) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ALXO Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALXO Bull vs. Bear Conversation Board β€” What's Your Call at $1.37?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALXO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ALXO:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER β€’ Price Action & Volume Trader πŸ‚ BULLISH 🎯 Target: $1.59 (+30.3%)
πŸ“Œ Pinned Debate

Debt/Equity of 0.17 and an Altman Z of 2.5 show the balance sheet is the rating's relative strength, with operating losses narrowing fr

Here is why I am bullish on ALXO here at $1.22: Debt/Equity of 0.17 and an Altman Z of 2.5 show the balance sheet is the rating's relative strength, with operating losses narrowing from -$170.3M to -$104.0M.. Compare ALXO's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $1.16 are getting bought.

ArenaChamp_24 πŸ‚ BULL

@TapeReader_Pro Agree on the RQD 44/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.22 and keeping dry powder in case we test $1.13.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $1.01 (-17.2%)
Spot @ $1.22

ROIC of -35%, 0% FCF yield, and -$84.4M of FY 2025 free-cash-flow burn against $16.4M cash point to continued capital consumption.

I respect the product at ALX Oncology Holdings Inc., but the stock at $1.22 is a different story. ROIC of -35%, 0% FCF yield, and -$84.4M of FY 2025 free-cash-flow burn against $16.4M cash point to continued capital consumption.. FCF yield is 0.0% and RQD sits at 44/100 (D) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE